Correlation analysis of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia

doi:10.3969/j.issn.1673-8640.2022.011.003

Abstract

Abstract:

Objective To evaluate the relationship of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia（AML）. Methods From July 2016 to March 2017，80 elderly patients with AML in Quzhou People’s Hospital were enrolled，and 32 patients with non malignant blood diseases undergoing bone marrow biopsy were enrolled as control group. The general clinical data，cytogenetic and molecular biological data of AML group were collected. The relative expression of PBK/TOPK in bone marrow mononuclear cells was determined by real-time fluorescence quantitative polymerase chain reaction（RT-qPCR）. The AML group was treated with induction therapy，and the complete remission（CR） rate was calculated. The patients were followed up for 3 years. The survival curve was drawn by Kaplan-Meier method. The relationship between PBK/TOPK expression level and overall survival（OS） and event free survival（EFS） was analyzed. Results The results of RT-qPCR showed that the expression of PBK/TOPK in bone marrow mononuclear cells of elderly patients with AML was higher than that of control group. The expression level of PBK/TOPK was related to hemoglobin（Hb），platelet（PLT）count，chromosome karyotype and gene mutation. The high expression of PBK/TOPK had low CR rate（P<0.05）. The results of survival analysis showed that the 3-year survival rate of PBK/TOPK low expression group was higher than that of PBK/TOPK high expression group（P<0.05），and the EFS of patients with high PBK/TOPK expression was lower than that of patients with PBK/TOPK low expression（P<0.05）. Conclusions The expression of PBK/TOPK in elderly patients with AML is higher，and its high expression is related to the clinical characteristics of patients，which has a predictive value for the survival and prognosis of elderly patients with AML.

Key words: PBK/TOPK, Acute myeloid leukemia, Elder population, Treatment response, Survival time

CLC Number:

R393

WU Wenping, XU Linjuan, WANG Jiaheng, ZHANG Nana. Correlation analysis of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia[J]. Laboratory Medicine, 2022, 37(11): 1017-1022.

Figures/Tables 5

References 21

[1]	王霞, 张斌. 混合表型急性白血病患者骨髓细胞形态学与流式免疫表型特点[J]. 检验医学, 2019, 34(3):235-239.
[2]	张校辉, 邢江涛, 张玉娜, 等. 变异性急性早幼粒细胞白血病实验室检查结果分析[J]. 检验医学, 2019, 34(10):871-875.
[3]	ABRAHÃO R, HUYNH J C, BENJAMIN D J, et al. Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults:a population-based study[J]. Int J Epidemiol, 2021, 50(2):663-674. DOI URL
[4]	齐瑶, 赵明峰, 肖霞, 等. 地西他滨联合减量FLAG方案治疗老年高危急性髓系白血病患者的临床疗效观察[J]. 中国实验血液学杂志, 2020, 28(5):1440-1444.
[5]	董杨, 邓来军, 展昭民, 等. 地西他滨联合小剂量米托蒽醌预激方案治疗老年急性髓系白血病的疗效及安全性研究[J]. 中国实用内科杂志, 2020, 40(7):567-570.
[6]	张伟. PBK/TOPK在宫颈癌组织中的表达及临床意义[J]. 中国免疫学杂志, 2015, 31(12):1688-1691.
[7]	贾建民, 葛永超, 段堃, 等. PBK/TOPK表达对膀胱癌BIU-87细胞株增殖及迁移的影响[J]. 国际泌尿系统杂志, 2020, 40(1):5-8.
[8]	李晓勇, 刘涛, 李建, 等. PBK/TOPK在乳腺癌细胞中介导MEK非依赖性ERK激活中作用机制分析[J]. 中国细胞生物学学报, 2020, 42(1):55-61.
[9]	VARDIMAN J W, HARRIS N L, BRUNNING R D. The World Health Organization(WHO)classification of the myeloid neoplasms[J]. Blood, 2002, 100(7):2292-2302. DOI URL
[10]	张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007.
[11]	BELL J A, GALAZNIK A, HUELIN R, et al. Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia:asystematic literature review[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(7):e303-e314. DOI URL
[12]	EFFICACE F, BRECCIA M, AVVISATI G, et al. Health-related quality of life,symptom burden,and comorbidity in long-term survivors of acute promyelocytic leukemia[J]. Leukemia, 2019, 33(7):1598-1607. DOI URL
[13]	CHEBIHI Z T, BELKHAYAT A, CHADLI E, et al. Cytogenetic profile of moroccan pediatric acute lymphoblastic leukemia:analysis of 155 cases with a review of the literature[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(6):e241-e248. DOI URL
[14]	徐敏, 吴晓. 老年急性髓系白血病诱导治疗疗效与预后分析[J]. 中国临床研究, 2019, 32(3):367-370.
[15]	SCHNEIDER F, HOSTER E, SCHNEIDER S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML(NK-AML)[J]. Ann Hematol, 2012, 91(1):9-18. DOI URL
[16]	LIU Y, LIU H, CAO H, et al. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis[J]. Oncol Rep, 2015, 34(6):3288-3296. DOI URL
[17]	ALACHKAR H, MUTONGA M, MALNASSY G, et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia[J]. Oncotarget, 2015, 6(32):33410-33425. DOI PMID
[18]	SIMONS-EVELYN M, BAILEY-DELL K, TORETSKY J A, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis, 2001, 27(5):825-829. DOI URL
[19]	田鑫, 贺湘玲, 袁小叶, 等. TOPK/PBK在儿童恶性淋巴瘤与淋巴结反应性增生的淋巴结组织表达的研究[J]. 中国当代儿科杂志, 2018, 20(3):214-217.
[20]	陈渠发, 陈毅斌, 张锡迎, 等. PBK/TOPK在HCC组织中的表达与HCC对奥沙利铂敏感性的关系研究[J]. 解放军预防医学杂志, 2019, 37(3):35-37.
[21]	盛俊杰, 万岁桂. 红系增生髓系肿瘤的诊断分类演变[J]. 白血病·淋巴瘤, 2019, 28(2):125-128.

组别	例数	CR	非CR
PBK/TOPK高表达组	49	15（30.61）	34（69.39）
PBK/TOPK低表达组	31	21（67.74）	10（32.26）

组别	例数	CR	非CR
PBK/TOPK高表达组	49	15（30.61）	34（69.39）
PBK/TOPK低表达组	31	21（67.74）	10（32.26）